^
Association details:
| Biomarker: | BRAF K601E |
|---|---|
| Cancer: | Melanoma |
| Drug: | Mekinist (trametinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma
Excerpt:
We carried out a retrospective analysis of efficacy and safety in four patients with BRAF K601E and one patient with L597Q mutation-positive metastatic melanoma treated with the MEK inhibitor trametinib. Three patients achieved a RECIST partial response, including the patient with an L597Q mutation...Trametinib has antitumour activity in patients with BRAF K601E and L597Q mutation-positive metastatic melanoma.
DOI:
10.1097/CMR.0000000000000099
Source:
Title:
Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
Excerpt:
One patient each with BRAF K601E and BRAF V600R had prolonged PR.
DOI:
10.1200/JCO.2012.43.5966
Trial ID:
Source:
Title:
5348 / 30 - Targeting MEK, alone and in combination with BRAF, in metastatic BRAFK601E-mutated melanoma
Published date:
03/15/2023
Excerpt:
Melanoma cell line (MeWo) was transfected with doxycycline-inducible vector encoding wild-type or K601E-mutant BRAF. Subsequently, cells or xenograft-bearing mice were treated with trametinib, dabrafenib plus trametinib or sorafenib plus trametinib. Compared with BRAF WT, MTT assay demonstrated that BRAF K601E cells were more sensitive towards drug treatment. The effects of combined treatment were more profound. Tumorigenicity assay showed that trametinib treatment inhibited tumor growth of BRAFK601E xenografts.
